TB R&D Weekly Update: Podcast Interview with Dr. Yossef Av-Gay

Dr. Yossef Av-Gay

Listen to Youssef Av-Gay Podcast

Summary: Dr. Yossef Av-Gay, a professor in the Division of Infectious Diseases at the University of British Columbia, recently published a paper in the Proceedings of the National Academy of Sciences (PNAS) entitled “Mycobacterium tuberculosis protein tyrosine phosphatase (PtpA) excludes host vacuolar-H+–ATPase to inhibit phagosome acidification.” The paper provides evidence to that points to a specific protein that allows Mtb to bypass the body’s defenses. In this interview, we discuss the recently published paper, his contribution to TB drug discovery and the focus of his research.

Dr. Av-Gay’s Laboratory research is focused on the molecular pathogenesis of Mycobacterium tuberculosis in order to identify new targets for drug therapy. Using bioinformatic and pathogenomic tools, we have identified three molecular targets and we are now characterizing them for their contribution to TB pathogenesis. These targets are protein kinases of M. tuberculosis, mycothiol production and cholesterol utilization by mycobacteria.

Additional Coverage:

The stealth art of infectious agents: researchers uncover why the body can’t defend against tuberculosis

Additional TB R&D News:

2011 WGND Annual Meeting Recap now available!

IDRI Announces New VP Tuberculosis Drug Development

UK and Indian researchers unite to fight global tuberculosis epidemic

South Africa: Fight against TB yielding positive results

TB risk increases in early pregnancy, study shows

Global Tuberculosis Diagnostics Market: Growth Opportunities and Business Expansion Strategies

Discordance Among Commercially-Available Diagnostics For Latent Tuberculosis Infection

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...